Archive:
Digitalization offers great opportunities to provide patients with better care, as several model projects show. To be successful, doctors don't just need large, high-quality data pools and algorithms. Data protection and data security play an important role, but should not become a fig leaf to reject everything new.
04.04.2019
More than every second person in Germany, specifically 54.3% of the population, has limited health literacy - according to the results of a study by Bielefeld University. This means that the majority of the population in Germany finds it difficult to find, understand, evaluate and use health-related information.
04.04.2019
It is intended to advance healthcare and promote innovation - the Innovatinos Fund. With a total volume of 820 million euros, 290 projects were funded in the first phase between 2016 and 2018. The Federal Ministry of Health has now initiated a scientific evaluation of the funding from the Innovation Fund. Is the fund a suitable instrument to further develop healthcare? The authors of the interim report - the final report is to be submitted to the German Bundestag by March 31, 2021 - answered this question with yes.
04.04.2019
Christian Klose, previously permanent representative of Department 5 “Digitalization and Innovation” in the Federal Ministry of Health and since the beginning of April sub-department head in the department headed by Dr. Gottfried Ludewig, gave an insight into the timetable of the digitalization law, which is about to be finalized, at a lecture evening on the occasion of the DNVF SpringSchool: The BMG, which has almost 800 employees, is currently in the process of getting this law off the ground. The draft bill for this proposed law (see p. 23), which should actually have been ready at the turn of the year, is now available.
04.04.2019
Increasing the efficiency of clinical studies is possible with the help of patient health data from various sources. The US Food and Drug Administration (FDA) is convinced of this theory, which is still controversial in this country. But what does the data have to be like in order to provide valid results and evidence? And how should these results be incorporated into the FDA's regulatory decision-making? The US authority addresses these questions with some interesting answers in the “Framework for FDA'S Real-World Evidence Program”.
04.04.2019
What does big data mean for the EU regulation of national health systems? The newly founded task force of the HMA (Heads of Medicines Agencies) and EMA (European Medicines Agencies) is addressing this question. What data is generated, in what quality, and what standards are necessary to use this data to manage the healthcare system? These are some aspects of the topic that the task force has developed in various workstreams. She has summarized the results in a report, including several core recommendations and two studies on how industry and the responsible national supervisory authorities (National Competent Authorities, NCAs) deal with big data.
04.04.2019
When it comes to health economics issues in Germany, you come to Prof. Dr. Jürgen Wasem, the holder of the Alfried Krupp von Bohlen and Halbach Endowed Chair for Medical Management at the University of Duisburg-Essen. On countless podiums and as chairman of the advisory board of various specialist committees, he always raises his voice when he wants to point out undesirable developments from his economic perspective or show how our health system can become even better; for example, by becoming more open to innovation.
04.04.2019
When it comes to health economics issues in Germany, you come to Prof. Dr. Jürgen Wasem, the holder of the Alfried Krupp von Bohlen and Halbach Endowed Chair for Medical Management at the University of Duisburg-Essen. On countless podiums and as chairman of the advisory board of various specialist committees, he always raises his voice when he wants to point out undesirable developments from his economic perspective or show how our health system can become even better; for example, by becoming more open to innovation.
04.04.2019
“Reference Pricing in Germany: Implications for US Pharmaceutical Purchasing” 1,4 and “Pharmaceutical Reference Pricing: Does It Have a Future in the US?”2 are the titles of two scientific articles written by Prof. James C. Robinson PhD, MPH, has already published as part of his study funded by the Commonwealth Funds3. The Professor of Health Economics and Director of the Berkeley Center for Health Technology (BCHT) at the University of California at Berkeley presented his findings to the participants of a BMC background discussion in his lecture “An American in Berlin: Insights on Drug Assessment and Pricing under AMNOG”. he explains further in an interview with “Monitor Healthcare Research”.
04.04.2019
On the occasion of the Roche symposium “Oncology of the Future. “How are personalized medicine and big data changing healthcare?” At this year’s Capital Congress, “Monitor Healthcare Research” spoke to Dr. Johannes Bruns, Secretary General of the German Cancer Society, and PD Dr. Claus Lattrich, Head of Personalized Healthcare at Roche Pharma AG, Grenzach-Wyhlen. The focus of the conversation was the question of how data from oncological care can be collected, networked, analyzed and then used in a standardized manner to create better care. Both Bruns and Lattrich agreed on this: The networking of digital patient data is associated with a high benefit for research and care, but can only be successful if everyone involved in the system works together.